Peter Feinberg
DirectorMr. Peter Feinberg is Strategic Advisor of Apricity Health, LLC. He has been an Independent Director of Notable Labs, Inc. since October16, 2023. He served as Board Observer at Nirogy Therapeutics Inc. since May 2021 until 2022. He served as Board Observer at Immuneering Corporation. Mr. Feinberg serves as Founding Partner at Boxcar PMJ LLC. He served as Head of Trading for U.S. Equity Division at Oppenheimer & Co. Inc. until January 2015. He serves as a Director of Immuneering Corporation since January 2021. Mr. Feinberg served as the Managing Director and Head of Institutional Equities Trading at Oppenheimer & Co. Inc. since August 2004. Mr. Feinberg originally joined Oppenheimer in 1982 and subsequently held various senior positions including the head of that firm's Los Angeles Office and head of Equity Sales Trading. Upon the sale of Oppenheimer to CIBC in 1997, Mr. Feinberg joined CIBC World Markets, the capital markets division of CIBC. After leaving CIBC in 2002, Mr. Feinberg joined IA Englander & Co, as a senior partner responsible for growing an equities direct access business. He is a founding member of Boxcar Partners. He is a founder of multiple companies including BridgeBio, which invests in preclinical, non-public, rare genetic disease assets, North Coast Partners, a real estate holding company that invests in Detroit. He is an advisory board member of Ignite Power, which has created a life changing experience for its citizens and Sporos Bioventures. Mr. Feinberg received his B.S. in finance from Whittier College.
公司職務
- 公司名稱Immuneering Corporation股票代碼IMRX職務Director共事同僚
- BJBenjamin J. ZeskindCo-Founder, President, CEO & Director
- TJThomas J. SchallChairman of the Board
- RJRobert J. CarpenterCo-Founder & Chair Emeritus
- BMBrett M. HallChief Scientific Officer
- MDMichael D. BookmanChief Legal Officer & Secretary
- AWAndrew W. GengosCFO & Treasurer
- LBLaurie Bartlett KeatingIndependent Director
- 公司名稱Notable Labs, Ltd.股票代碼NTBLQ職務Independent Director共事同僚
- SAScott Alan McPhersonChief Financial Officer
- TPTuomo PatsiIndependent Chairman
- JPJoseph P. WagnerChief Scientific Officer
- KZKaile ZaggerInterim CEO & Chief Restructuring Officer
- GCGlenn C. MichelsonChief Medical Officer
- TIThomas I. H. DubinIndependent External Director
- TGThomas GraneyIndependent External Director
- PFPeter FeinbergIndependent Director
- MGMichele GalenIndependent Director
